Shanthi V. Sitaraman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shanthi V. Sitaraman has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Didier Merlin
Division of Digestive Diseases, Emory University Atlanta, GA
14 shared publicationsAndrew T. Gewirtz
Department of Pathology, Emory University Atlanta, GA
9 shared publicationsLixin Wang
Division of Digestive Diseases, 2Department of Pathology, Emory University, Atlanta, Georgia
8 shared publicationsVasantha L. Kolachala
Division of Digestive Diseases Emory University Atlanta Georgia USA
5 shared publicationsJesse Roman
4 shared publicationsPallavi Garg
Division of Digestive Diseases, Emory University, Atlanta, GA 30322, USA
4 shared publications
Latest Publications
- 10 October 2010
- Published by Springer Nature in Nature Materials
- Vol. 9 (11) , 923-928
Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestines
The oral delivery of small interfering RNA (siRNA) to diseased intestinal tissue is challenging because of the harsh environment created by gastrointestinal fluids and mucosa. Now, such delivery of siRNA to sites of intestinal inflammation is achieved using polythioketal nanoparticles and gene expression is successfully inhibited in the inflamed tissue. Small interfering RNAs (siRNAs) directed against proinflammatory cytokines have the potential to treat numerous diseases associated with intestinal inflammation1; however, the side-effects caused by the systemic depletion of cytokines2,3,4 demands that the delivery of cytokine-targeted siRNAs be localized to diseased intestinal tissues. Although various delivery vehicles have been developed to orally deliver therapeutics to intestinal tissue5,6,7, none of these strategies has demonstrated the ability to protect siRNA from the harsh environment of the gastrointestinal tract and target its delivery to inflamed intestinal tissue. Here, we present a delivery vehicle for siRNA, termed thioketal nanoparticles (TKNs), that can localize orally delivered siRNA to sites of intestinal inflammation, and thus inhibit gene expression in inflamed intestinal tissue. TKNs are formulated from a polymer, poly-(1,4-phenyleneacetone dimethylene thioketal), that degrades selectively in response to reactive oxygen species (ROS). Therefore, when delivered orally, TKNs release siRNA in response to the abnormally high levels of ROS specific to sites of intestinal inflammation8,9,10. Using a murine model of ulcerative colitis, we demonstrate that orally administered TKNs loaded with siRNA against the proinflammatory cytokine tumour necrosis factor-alpha (TNF-α) diminish TNF-α messenger RNA levels in the colon and protect mice from ulcerative colitis.
- 10 October 2010
- Published by Springer Nature in Nature Materials
- Vol. 9 (11) , 923-928
Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestines
The oral delivery of small interfering RNA (siRNA) to diseased intestinal tissue is challenging because of the harsh environment created by gastrointestinal fluids and mucosa. Now, such delivery of siRNA to sites of intestinal inflammation is achieved using polythioketal nanoparticles and gene expression is successfully inhibited in the inflamed tissue. Small interfering RNAs (siRNAs) directed against proinflammatory cytokines have the potential to treat numerous diseases associated with intestinal inflammation1; however, the side-effects caused by the systemic depletion of cytokines2,3,4 demands that the delivery of cytokine-targeted siRNAs be localized to diseased intestinal tissues. Although various delivery vehicles have been developed to orally deliver therapeutics to intestinal tissue5,6,7, none of these strategies has demonstrated the ability to protect siRNA from the harsh environment of the gastrointestinal tract and target its delivery to inflamed intestinal tissue. Here, we present a delivery vehicle for siRNA, termed thioketal nanoparticles (TKNs), that can localize orally delivered siRNA to sites of intestinal inflammation, and thus inhibit gene expression in inflamed intestinal tissue. TKNs are formulated from a polymer, poly-(1,4-phenyleneacetone dimethylene thioketal), that degrades selectively in response to reactive oxygen species (ROS). Therefore, when delivered orally, TKNs release siRNA in response to the abnormally high levels of ROS specific to sites of intestinal inflammation8,9,10. Using a murine model of ulcerative colitis, we demonstrate that orally administered TKNs loaded with siRNA against the proinflammatory cytokine tumour necrosis factor-alpha (TNF-α) diminish TNF-α messenger RNA levels in the colon and protect mice from ulcerative colitis.
- Open Access
- 13 January 2010
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (2) , 792-801
Matrix Metalloproteinase-9 Functions as a Tumor Suppressor in Colitis-Associated Cancer
There is a well-documented association of matrix metalloproteinase-9 (MMP-9) and receptor Notch-1 overexpression in colon cancer. We recently showed that MMP-9 is also upregulated in colitis, where it modulates tissue damage and goblet cell differentiation via proteolytic cleavage of Notch-1. In this study, we investigated whether MMP-9 is critical for colitis-associated colon cancer (CAC). Mice that are wild type (WT) or MMP-9 nullizygous (MMP-9−/−) were used for in vivo studies and the human enterocyte cell line Caco2-BBE was used for in vitro studies. CAC was induced in mice using an established carcinogenesis protocol that involves exposure to azoxymethane followed by treatment with dextran sodium sulfate. MMP-9−/− mice exhibited increased susceptibility to CAC relative to WT mice. Elevations in tumor multiplicity, size, and mortality were associated with increased proliferation and decreased apoptosis. Tumors formed in MMP-9−/− mice exhibited expression of p21WAF1/Cip1 and increased expression of β-catenin relative to WT mice. In vitro studies of MMP-9 overexpression showed increased Notch-1 activation with a reciprocal decrease in β-catenin. Notch and β-catenin/Wnt signaling have crucial roles in determining differentiation and carcinogenesis in gut epithelia. Despite being a mediator of proinflammatory responses in colitis, MMP-9 plays a protective role and acts as a tumor suppressor in CAC by modulating Notch-1 activation, thereby resulting in activation of p21WAF1/Cip1 and suppression of β-catenin. Cancer Res; 70(2); 792–801
- 13 January 2010
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (2) , 792-801
Open AccessMatrix Metalloproteinase-9 Functions as a Tumor Suppressor in Colitis-Associated Cancer
There is a well-documented association of matrix metalloproteinase-9 (MMP-9) and receptor Notch-1 overexpression in colon cancer. We recently showed that MMP-9 is also upregulated in colitis, where it modulates tissue damage and goblet cell differentiation via proteolytic cleavage of Notch-1. In this study, we investigated whether MMP-9 is critical for colitis-associated colon cancer (CAC). Mice that are wild type (WT) or MMP-9 nullizygous (MMP-9−/−) were used for in vivo studies and the human enterocyte cell line Caco2-BBE was used for in vitro studies. CAC was induced in mice using an established carcinogenesis protocol that involves exposure to azoxymethane followed by treatment with dextran sodium sulfate. MMP-9−/− mice exhibited increased susceptibility to CAC relative to WT mice. Elevations in tumor multiplicity, size, and mortality were associated with increased proliferation and decreased apoptosis. Tumors formed in MMP-9−/− mice exhibited expression of p21WAF1/Cip1 and increased expression of β-catenin relative to WT mice. In vitro studies of MMP-9 overexpression showed increased Notch-1 activation with a reciprocal decrease in β-catenin. Notch and β-catenin/Wnt signaling have crucial roles in determining differentiation and carcinogenesis in gut epithelia. Despite being a mediator of proinflammatory responses in colitis, MMP-9 plays a protective role and acts as a tumor suppressor in CAC by modulating Notch-1 activation, thereby resulting in activation of p21WAF1/Cip1 and suppression of β-catenin. Cancer Res; 70(2); 792–801
- Open Access
- 1 July 2009
- Published by Elsevier in Gastroenterology
- Vol. 137 (1) , 199-208.e6
Prohibitin Is a Novel Regulator of Antioxidant Response That Attenuates Colonic Inflammation in Mice
- 1 July 2009
- Published by Elsevier in Gastroenterology
- Vol. 137 (1) , 199-208.e6
Open AccessProhibitin Is a Novel Regulator of Antioxidant Response That Attenuates Colonic Inflammation in Mice
- Open Access
- 8 April 2009
- Published by Wiley in The FASEB Journal
- Vol. 23 (8) , 2727-2734
Adenosine 2B receptors (A 2B AR) on enteric neurons regulate murine distal colonic motility
Delayed colonic emptying leading to constipation is a significant health concern. We investigated the role of adenosine 2B receptor (A 2B AR) in modulating distal colonic motility using wild‐type and A 2B AR‐knockout ( A 2B AR –/– ) mice. Colon motility was assessed using stool characteristics and colonic transit. Distal colonic ganglia, isolated by laser capture microdissection, were tested for A 2B AR expression by RT‐ PCR. The distal colon contraction and relaxation responses were assessed by electrical field stimulation (EFS) in presence of A 2B AR agonists, antagonists or inhibitors of nitric oxide (NO) and guanylate cyclase. Nitrite levels were measured in enteric neuronal cultures exposed to A 2B AR agonists/antagonists. A 2B AR –/– mice display increased stool retention, decreased stool frequency, delayed colonic emptying, and decreased circular muscle relaxation. RT‐PCR identified A 2B AR expression in distal colonic ganglia. EFS studies revealed that enteric neuronal A 2B AR is essential for distal colonic relaxation, and A 2B AR antagonists can inhibit relaxation. Enteric neurons stimulated with A 2B AR agonists produced more nitrite than cultures treated with antagonists. We demonstrate an essential role of A 2B AR in regulating distal colon relaxation, as A 2B AR activation is linked to NO signaling. Hence targeting the colonic A 2B AR could represent a novel therapeutic strategy to treat constipation.— Chandrasekharan, B. P., Kolachala, V. L., Dalmasso, G., Merlin, D., Ravid, K., Sitaraman, S. V., Srinivasan, S. Adenosine 2B receptors (A2BAR) on enteric neurons regulate murine distal colonic motility. FASEB J. 23, 2727–2734 (2009)
- 8 April 2009
- Published by Wiley in The FASEB Journal
- Vol. 23 (8) , 2727-2734
Open AccessAdenosine 2B receptors (A 2B AR) on enteric neurons regulate murine distal colonic motility
Delayed colonic emptying leading to constipation is a significant health concern. We investigated the role of adenosine 2B receptor (A 2B AR) in modulating distal colonic motility using wild‐type and A 2B AR‐knockout ( A 2B AR –/– ) mice. Colon motility was assessed using stool characteristics and colonic transit. Distal colonic ganglia, isolated by laser capture microdissection, were tested for A 2B AR expression by RT‐ PCR. The distal colon contraction and relaxation responses were assessed by electrical field stimulation (EFS) in presence of A 2B AR agonists, antagonists or inhibitors of nitric oxide (NO) and guanylate cyclase. Nitrite levels were measured in enteric neuronal cultures exposed to A 2B AR agonists/antagonists. A 2B AR –/– mice display increased stool retention, decreased stool frequency, delayed colonic emptying, and decreased circular muscle relaxation. RT‐PCR identified A 2B AR expression in distal colonic ganglia. EFS studies revealed that enteric neuronal A 2B AR is essential for distal colonic relaxation, and A 2B AR antagonists can inhibit relaxation. Enteric neurons stimulated with A 2B AR agonists produced more nitrite than cultures treated with antagonists. We demonstrate an essential role of A 2B AR in regulating distal colon relaxation, as A 2B AR activation is linked to NO signaling. Hence targeting the colonic A 2B AR could represent a novel therapeutic strategy to treat constipation.— Chandrasekharan, B. P., Kolachala, V. L., Dalmasso, G., Merlin, D., Ravid, K., Sitaraman, S. V., Srinivasan, S. Adenosine 2B receptors (A2BAR) on enteric neurons regulate murine distal colonic motility. FASEB J. 23, 2727–2734 (2009)
- 1 February 2009
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 296 (2) , G175-G184
Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis
Matrix metalloproteinases (MMP) play an important role in pathogenesis of inflammatory bowel disease (IBD). Two known gelatinases, MMP-2 and MMP-9, are upregulated during IBD. Epithelial-derived MMP-9 is an important mediator of tissue injury in colitis, whereas MMP-2 protects against tissue damage and maintains gut barrier function. It has been suggested that developing strategies to block MMP-9 activity in the gut might be of benefit to IBD. However, given that MMP-2 and MMP-9 are structurally similar, such approaches would also likely inhibit MMP-2. Thus, to gain insight into outcome of inhibiting both MMP-2 and MMP-9, MMP-2−/−/MMP-9−/−double knockout mice (dKO) lacking both MMP-2 and MMP-9 were used in this study. Three models of murine colitis were used: dextran sodium sulfate (DSS), Salmonella typhimurium (S.T.), and trinitrobenzene sulfonic acid (TNBS). Our data demonstrate that MMP-2 and MMP-9 activities were highly upregulated in wild-type (WT) mice treated with DSS, S.T., or TNBS whereas dKO mice were resistant to the development of colitis. WT mice had extensive inflammation and tissue damage compared with dKO mice as suggested by histological assessment and myeloperoxidase activity. In conclusion, these results suggest an overriding role of MMP-9 in mediating tissue injury compared with the protective role of MMP-2 in development of colitis. Thus inhibition of MMP-9 may be beneficial in treatment of colitis even if resulting in inhibition of MMP-2.
- 1 February 2009
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 296 (2) , G175-G184
Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis
Matrix metalloproteinases (MMP) play an important role in pathogenesis of inflammatory bowel disease (IBD). Two known gelatinases, MMP-2 and MMP-9, are upregulated during IBD. Epithelial-derived MMP-9 is an important mediator of tissue injury in colitis, whereas MMP-2 protects against tissue damage and maintains gut barrier function. It has been suggested that developing strategies to block MMP-9 activity in the gut might be of benefit to IBD. However, given that MMP-2 and MMP-9 are structurally similar, such approaches would also likely inhibit MMP-2. Thus, to gain insight into outcome of inhibiting both MMP-2 and MMP-9, MMP-2−/−/MMP-9−/−double knockout mice (dKO) lacking both MMP-2 and MMP-9 were used in this study. Three models of murine colitis were used: dextran sodium sulfate (DSS), Salmonella typhimurium (S.T.), and trinitrobenzene sulfonic acid (TNBS). Our data demonstrate that MMP-2 and MMP-9 activities were highly upregulated in wild-type (WT) mice treated with DSS, S.T., or TNBS whereas dKO mice were resistant to the development of colitis. WT mice had extensive inflammation and tissue damage compared with dKO mice as suggested by histological assessment and myeloperoxidase activity. In conclusion, these results suggest an overriding role of MMP-9 in mediating tissue injury compared with the protective role of MMP-2 in development of colitis. Thus inhibition of MMP-9 may be beneficial in treatment of colitis even if resulting in inhibition of MMP-2.
- Open Access
- 1 September 2008
- Published by Elsevier in Gastroenterology
- Vol. 135 (3) , 861-870
A2B Adenosine Receptor Gene Deletion Attenuates Murine Colitis
- 1 September 2008
- Published by Elsevier in Gastroenterology
- Vol. 135 (3) , 861-870
Open AccessA2B Adenosine Receptor Gene Deletion Attenuates Murine Colitis
- Open Access
- 1 September 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (1) , 127-137
Blockade of adenosine A2B receptors ameliorates murine colitis
Background and purpose: The adenosine 2B (A2B) receptor is the predominant adenosine receptor expressed in the colon. Acting through the A2B receptor, adenosine mediates chloride secretion, as well as fibronectin and interleukin (IL)‐6 synthesis and secretion in intestinal epithelial cells. A2B receptor mRNA and protein expression are increased during human and murine colitis. However, the effect of the A2B receptor in the activation of the intestinal inflammatory response is not known. In this study, we examined the effect of A2B receptor antagonism on murine colitis.Experimental approach: Dextran sodium sulphate (DSS)‐treated mice and piroxicam‐treated IL‐10−/− mice were used as animal models of colitis. The A2B receptor‐selective antagonist, ATL‐801, was given in the diet.Key results: Mice fed ATL‐801 along with DSS showed a significantly lower extent and severity of colitis than mice treated with DSS alone, as shown by reduced clinical symptoms, histological scores, IL‐6 levels and proliferation indices. The administration of ATL‐801 prevented weight loss, suppressed the inflammatory infiltrate into colonic mucosa and decreased epithelial hyperplasia in piroxicam‐treated IL‐10−/− mice. IL‐6 and keratinocyte‐derived chemokine (KC) concentrations in the supernatants of colonic organ cultures from colitic mice were significantly reduced by ATL‐801 administration.Conclusions and implications: Taken together, these data demonstrate that the intestinal epithelial A2B receptor is an important mediator of pro‐inflammatory responses in the intestine and that A2B receptor blockade may be an effective therapeutic strategy to treat inflammatory bowel disease.British Journal of Pharmacology (2008) 155, 127–137; doi:10.1038/bjp.2008.227; published online 9 June 2008
- 1 September 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (1) , 127-137
Open AccessBlockade of adenosine A2B receptors ameliorates murine colitis
Background and purpose: The adenosine 2B (A2B) receptor is the predominant adenosine receptor expressed in the colon. Acting through the A2B receptor, adenosine mediates chloride secretion, as well as fibronectin and interleukin (IL)‐6 synthesis and secretion in intestinal epithelial cells. A2B receptor mRNA and protein expression are increased during human and murine colitis. However, the effect of the A2B receptor in the activation of the intestinal inflammatory response is not known. In this study, we examined the effect of A2B receptor antagonism on murine colitis.Experimental approach: Dextran sodium sulphate (DSS)‐treated mice and piroxicam‐treated IL‐10−/− mice were used as animal models of colitis. The A2B receptor‐selective antagonist, ATL‐801, was given in the diet.Key results: Mice fed ATL‐801 along with DSS showed a significantly lower extent and severity of colitis than mice treated with DSS alone, as shown by reduced clinical symptoms, histological scores, IL‐6 levels and proliferation indices. The administration of ATL‐801 prevented weight loss, suppressed the inflammatory infiltrate into colonic mucosa and decreased epithelial hyperplasia in piroxicam‐treated IL‐10−/− mice. IL‐6 and keratinocyte‐derived chemokine (KC) concentrations in the supernatants of colonic organ cultures from colitic mice were significantly reduced by ATL‐801 administration.Conclusions and implications: Taken together, these data demonstrate that the intestinal epithelial A2B receptor is an important mediator of pro‐inflammatory responses in the intestine and that A2B receptor blockade may be an effective therapeutic strategy to treat inflammatory bowel disease.British Journal of Pharmacology (2008) 155, 127–137; doi:10.1038/bjp.2008.227; published online 9 June 2008
- Open Access
- 1 November 2007
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (45) , 32965-32973
Epithelial-derived Fibronectin Expression, Signaling, and Function in Intestinal Inflammation
- 1 November 2007
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (45) , 32965-32973
Open AccessEpithelial-derived Fibronectin Expression, Signaling, and Function in Intestinal Inflammation
- Open Access
- 1 May 2007
- Published by Elsevier in Gastroenterology
- Vol. 132 (5) , 1877-1889
Matrix Metalloproteinase-9 Regulates MUC-2 Expression Through Its Effect on Goblet Cell Differentiation
- 1 May 2007
- Published by Elsevier in Gastroenterology
- Vol. 132 (5) , 1877-1889
Open AccessMatrix Metalloproteinase-9 Regulates MUC-2 Expression Through Its Effect on Goblet Cell Differentiation
- 15 September 2006
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 177 (6) , 4103-4112
Selective Ablation of Matrix Metalloproteinase-2 Exacerbates Experimental Colitis: Contrasting Role of Gelatinases in the Pathogenesis of Colitis
The matrix metalloproteinases (MMPs), MMP-2 and MMP-9, share structural and substrate similarities and are up-regulated during human as well as animal models of inflammatory bowel disease. We recently demonstrated that epithelial-derived MMP-9 is an important mediator of inflammation and tissue damage in colitis. In this study, we examined the role of MMP-2 in acute colitis. Colitis was induced using two models, administration of dextran sodium sulfate (DSS) and Salmonella enterica subsp. serovar Typhimurium (S.T.). Bone marrow chimeras were performed using bone marrow cells from wild-type (WT) and MMP-2−/− mice. Colitis was evaluated by clinical symptoms, myeloperoxidase assay, and histology. MMP-2 protein expression and activity were up-regulated in WT mice treated with DSS or S.T. MMP-2−/− mice were highly susceptible to the development of colitis induced by DSS (or S.T.) compared with WT. During inflammation, MMP-2 expression was increased in epithelial cells as well as in the infiltrating immune cells. Bone marrow chimera demonstrated that mucosa-derived MMP-2 was required for its protective effects toward colitis. Furthermore, we demonstrate that severe colitis in MMP-2−/− is not due to a compensatory increase in MMP-9. Finally, we show that MMP-2 regulates epithelial barrier function. In contrast to MMP-9, mucosa-derived MMP-2 may be a critical host factor that is involved in the prevention or cessation of the host response to luminal pathogens or toxins, an important aspect of healing and tissue resolution. Together, our data suggest that a critical balance between the two gelatinases determines the outcome of inflammatory response during acute colitis.
- 15 September 2006
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 177 (6) , 4103-4112
Selective Ablation of Matrix Metalloproteinase-2 Exacerbates Experimental Colitis: Contrasting Role of Gelatinases in the Pathogenesis of Colitis
The matrix metalloproteinases (MMPs), MMP-2 and MMP-9, share structural and substrate similarities and are up-regulated during human as well as animal models of inflammatory bowel disease. We recently demonstrated that epithelial-derived MMP-9 is an important mediator of inflammation and tissue damage in colitis. In this study, we examined the role of MMP-2 in acute colitis. Colitis was induced using two models, administration of dextran sodium sulfate (DSS) and Salmonella enterica subsp. serovar Typhimurium (S.T.). Bone marrow chimeras were performed using bone marrow cells from wild-type (WT) and MMP-2−/− mice. Colitis was evaluated by clinical symptoms, myeloperoxidase assay, and histology. MMP-2 protein expression and activity were up-regulated in WT mice treated with DSS or S.T. MMP-2−/− mice were highly susceptible to the development of colitis induced by DSS (or S.T.) compared with WT. During inflammation, MMP-2 expression was increased in epithelial cells as well as in the infiltrating immune cells. Bone marrow chimera demonstrated that mucosa-derived MMP-2 was required for its protective effects toward colitis. Furthermore, we demonstrate that severe colitis in MMP-2−/− is not due to a compensatory increase in MMP-9. Finally, we show that MMP-2 regulates epithelial barrier function. In contrast to MMP-9, mucosa-derived MMP-2 may be a critical host factor that is involved in the prevention or cessation of the host response to luminal pathogens or toxins, an important aspect of healing and tissue resolution. Together, our data suggest that a critical balance between the two gelatinases determines the outcome of inflammatory response during acute colitis.